Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
Injectable peptides like CJC-1295 are still largely experimental, and clinicians should be cautious about their use due to uncertain efficacy and safety risks.
Where it sits
this study against the rest of the cjc-1295 corpusSummary and findings
This structured narrative review summarizes evidence regarding injectable peptides in sports medicine, focusing on their safety and efficacy. It highlights that while some peptides, like glucagon-like peptide-1 receptor agonists, show evidence for symptomatic improvement in knee osteoarthritis, others, including CJC-1295, remain investigational. The review emphasizes the need for caution in clinical use due to concerns about product quality and antidoping implications.
Abstract
<h4>Background</h4>Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancements; however, clinical adoption has outpaced high-quality evidence and regulatory consensus.<h4>Purpose</h4>To summarize contemporary human and translational evidence (January 1, 2020-August 31, 2025) for injectable peptides relevant to orthopaedics and sports medicine, and to clarify safety, product quality, regulatory, antidoping implications, and clinical outcomes.<h4>Study design</h4>Structured narrative review.<h4>Methods</h4>PubMed/MEDLINE, Embase, and Web of Science were searched (January 1, 2020-August 31, 2025). Eligible studies included randomized controlled trials, prospective human studies, and translational investigations directly applicable to musculoskeletal care; noninjectable formulations and nonmusculoskeletal indications were excluded. Results were synthesized qualitatively; risk of bias for human trials was appraised using standard tools.<h4>Results</h4>Five functional peptide classes were identified. Glucagon-like peptide-1 receptor agonists (e.g., semaglutide) are the only class supported by reproducible randomized evidence of symptomatic improvement in knee osteoarthritis, with benefits primarily mediated by clinically meaningful weight loss and putative anti-inflammatory effects, whereas structural cartilage modification remains unproven. Collagen-derived injectable preparations show preliminary postoperative symptom/early recovery benefits in small, single-center prospective human studies. Regenerative peptides (e.g., body protection compound-157 and thymosin derivatives) and growth hormone axis secretagogues (e.g., CJC-1295, ipamorelin, and tesamorelin) remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions.<h4>Conclusions</h4>Injectable peptides for sports medicine remain largely experimental. Clinical use should be confined to approved metabolic agents for indicated conditions and to rigorously designed research protocols. Clinicians caring for athletes must counsel patients regarding uncertain efficacy, product quality, safety risks, and antidoping implications.<h4>Level of evidence</h4>Level V. See Instructions for Authors for a complete description of levels of evidence.<h4>Strength of recommendation taxonomy</h4>Predominantly C.
Background
The paper reviews the role of injectable peptides in sports medicine, a field where performance enhancement and safety are critical concerns. Prior studies have indicated various peptides may influence muscle growth and recovery, but comprehensive evidence regarding their efficacy and safety is limited. This review is significant as it aims to consolidate existing knowledge and address potential antidoping issues.
Methods
The review synthesizes findings from various studies related to injectable peptides, including CJC-1295. It does not specify a particular study design, population, or sample size, as it is a narrative review rather than a primary research study. The duration and specific doses of peptides discussed are not detailed in the abstract.
Results
Not reported in abstract.
Interpretation
The review highlights that while some peptides may show promise in enhancing athletic performance, the evidence remains inconclusive and often comes from studies with methodological limitations. The lack of robust clinical data raises questions about the clinical significance of the findings, particularly for CJC-1295. Confounding factors such as small sample sizes and potential biases in the studies reviewed limit the reliability of conclusions drawn.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Narrative review lacks original data.
- No specific findings on CJC-1295.
- Potential biases in reviewed studies.
- Small sample sizes in existing literature.